Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 41-47 , October 2004

Association of serum apolipoprotein C III levels and apolipoprotein C III gene Sst I polymorphism with carotid intima-media thickness in Chinese type 2 diabetic patients

Received 7 October 2003 ,Revised 12 February 2004 ,Accepted 20 February 2004.

References 

  1. T.C. Fagan, Scowers, Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy, Arch. Inter. Med. 159 (1999) 1033–1034.
  2. Davis TM, Millns H, Stratton IM, et al.  Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch. Intern. Med. 1999;159:1097–1103
  3. Wick U, Witt E, Engel W. Restriction fragment length polymorphisms at the apoprotein genes A I, C III and B-100 and in the 5′ flanking region of the insulin gene as possible markers of coronary heart disease. Clin. Genet. 1995;47:184–190
  4. Lorenzo FD, Rubba P, Monticelli A, et al.  Coronary heart disease, echo-doppler evidence of peripheral arterial disease and polymorphism of apolipoprotein B gene and apoA I/C III cluster. Angiology. 1993;44:785–790
  5. Russo GT, Meigs JB, Cupples LA, et al.  Association of the Sst-I polymorphism at the apoC3 gene locus with variations in lipid levels. Atherosclerosis. 2001;158:173–181
  6. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterio. Throm. 1991;11:1245–1249
  7. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complication. Part 1. Diagnosis and Classification of Diabetes Mellitus, World Health Organization, Geneva, 1999.
  8. Fan P, Liu B. Study on lipid and apolipoprotein composition of plasma VLDL, LDL and HDL in endogenous hypertriglyceridemia. J. West China Univ. Med. Sci. 1995;26:6–10
  9. H.A. Erlich, 1989, PCR Technology: Principles and Applications for DNA Amplification, first ed., Stockton Press, New York.
  10. Ren Y, Tian H, Liu R, et al.  Apo C III gene polymorphism in type 2 diabetic mellitus with hypertriglyceridemia. Chin. J. Endocrinol. Metab. 2000;16:220–223
  11. Onat A, Hergenc G, Sansoy V, et al.  Apolipoprotein C III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168:81–89
  12. Blankenhorn DH, Nessim SA, Johnson RL, et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–3240
  13. Blankenhorn DH, Azen SP, Kramsch DM, et al.  Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med. 1993;119:969–976
  14. Blankenhorn DH, Selzer RH, Crawford DW, et al.  Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:2–28
  15. Hodis HN, Mack WJ, LaBree L, et al.  Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann. Intern. Med. 1996;124:548–556
  16. Maeda N, Li H, Lee D, et al.  Targeted disruption of the apolipoprotein C III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 1995;269:23610–23616
  17. Ito Y, Azrolan N, O’Connell A, et al.  Hypertriglyceridemia as a result of human apo C III gene expression in transgenic mice. Science. 1990;249:790–793
  18. Aalto-Setala K, Fisher EA, Chen X, et al.  Mechanism of hypertriglyceridemia in human apolipoprotein C III transgenic mice. J. Clin. Invest. 1992;90:1889–1890
  19. Ebara T, Ramakrishnan R, Steiner G, et al.  Chylomicronemia due to apolipoprotein C III overexpression in apolipoprotein E-null mice. J. Clin. Invest. 1997;99:2672–2681
  20. Cohn JS, Batal R, Tremblay M, et al.  Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J. Lipid Res. 2003;44:1976–1983
  21. Marcoux C, Tremblay M, Fredenrich A, et al.  Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism. 2001;50:112–119
  22. Bruns GA, Karanthasis SK, Breslow JL. Human apolipoproteinA I-C III gene complex is located on chromosome 11. Arteriosclerosis. 1984;4:97–102
  23. Humphries SE. DNA polymorphism of the apolipoprotein genes-their use in the investigation of the genetic component of hyperlipidemia and atherosclerosis. Atherosclerosis. 1988;72:89–108
  24. Choi GR, Suh SP, Song JW, et al.  Genetic variation of the apoA I-C III-AIV gene cluster in hypertriglyceridemic patients with chronic renal failure undergoing hemodialysis. J. Korean Med. Sci. 2000;15:289–294

PII: S0168-8227(04)00060-9

doi: 10.1016/j.diabres.2004.02.020

Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 41-47 , October 2004

Article Tools

* Image Usage & Resolution